Angelini Pharma has secured development and commercialization rights from Sovargen for SVG-105, an antisense oligonucleotide candidate targeting intractable epilepsy, through a $550 million licensing agreement. SVG-105 is currently in preclinical development, representing a promising new therapeutic avenue for epilepsy patients with limited treatment options. This partnership aims to accelerate clinical progress and bring innovative therapies to market.